Previous Article |
Table of Contents
| Next Article
* Glycobiology Research and Training Center, Departments of Medicine
and Cellular and Molecular Medicine, University of California at San
Diego, La Jolla, CA 92093-0687; Edited by Morris Goodman, Wayne State University School of
Medicine, Detroit, MI, and approved July 18, 2002 (received for review April 30, 2002)
Humans are genetically deficient in the common mammalian sialic
acid N-glycolylneuraminic acid (Neu5Gc) because of an
Alu-mediated inactivating mutation of the gene encoding the
enzyme CMP-N-acetylneuraminic acid (CMP-Neu5Ac) hydroxylase
(CMAH). This mutation occurred after our last common ancestor
with bonobos and chimpanzees, and before the origin of present-day
humans. Here, we take multiple approaches to estimate the timing of
this mutation in relationship to human evolutionary history. First, we
have developed a method to extract and identify sialic acids from bones
and bony fossils. Two Neandertal fossils studied had clearly detectable
Neu5Ac but no Neu5Gc, indicating that the CMAH mutation predated the
common ancestor of humans and Neandertals, hominid evolution|sialic acids|Alu
sequences
Sialic acid (Sia) is a
generic term for a family of acidic monosaccharides found at the
terminal ends of sugar chains attached to cell surfaces and to soluble
glycoproteins (1-3). A major biochemical difference between humans and
other mammals, including the closest living relatives of humans
(chimpanzees and bonobos), is in the expression of the Sia
N-glycolylneuraminic acid (Neu5Gc). Whereas human tissues
and body fluids contain little or no detectable Neu5Gc, corresponding
samples from chimpanzees and bonobos (and the other great apes,
gorillas and orangutans) express high levels (4). Humans instead
express an excess of the precursor Sia N-acetylneuraminic
acid (Neu5Ac). Human deficiency of Neu5Gc is due to inactivation of the
gene for CMP-N-acetylneuraminic acid (CMP-Neu5Ac)
hydroxylase (CMAH), which converts CMP-Neu5Ac into CMP-Neu5Gc in other
animals (3, 5, 6).
Neu5Gc expression in non-human mammals is developmentally regulated and
tissue-specific (1, 2, 7-9), implying multiple biological roles. Some
Sia-binding proteins can distinguish Neu5Gc from Neu5Ac. Thus, the CMAH
mutation could have altered interactions involving
endogenous human receptors such as
sialoadhesin/Siglec-1 (10) and myelin-associated
glycoprotein/Siglec-4a (11), as well as the binding of
pathogenic microorganisms such as influenza A (12-14), rotaviruses
(15), and Escherichia coli K99 (16). Such differences could
have potentially affected human ontogeny, physiology, disease
susceptibility, and/or the ability of humans to domesticate livestock.
Human Neu5Gc deficiency is due to a 92-bp frame-shifting exon deletion
in the CMAH gene (5, 6) giving a markedly truncated protein (5),
lacking amino acid residues necessary for enzyme activity (17). This
mutation is homozygous in all human populations but absent in great
apes (3, 5, 18) Regardless of the original selection process(es) involved in human loss
of CMAH (e.g., a pathogen preferentially recognizing Neu5Gc as a host
receptor), there could have been secondary biological consequences.
Thus, determining when the mutation occurred would allow rational
hypotheses regarding its potential relationship to changes during human
evolution. Unfortunately, DNA sequence information is impossible to
retrieve from fossils older than Materials.
Epstein-Barr virus-transformed B cells from the great apes were kindly
provided by Peter Parham (Stanford University, Stanford, CA).
Contemporary primate bone samples were generously donated by the
Natural History Museum in San Diego. Faunal fossil samples (cave bear,
dugong, mammoth, etc.) were purchased from recognized dealers at the
1999 International Fossil Show in Tucson, AZ. Georgian Neandertal
fossils were kindly provided by Ivan Nasidze (22). Homo
erectus fossil samples (Solo skulls) found in Ngandong, East Java
in the 1930s as well as fossil fauna from Ngandong excavated in 1976 (23) were obtained from Gadjah Mada University in Yogyakarta, with
permission from Teuku Jacob. Kenyan fossil samples were collected from
sites in the Turkana Basin dating between 4 and 1.5 million years,
including Nariokotome, Nachukui, Kalachoro, Lomekwi, and Kanapoi to the
west of the modern lake, and Allia Bay and Koobi Fora to the east
(24-26).
Release, Purification, and Analysis of Sias from Bones and Fossils.
The surface of the bone or fossil was filed off, and a powdered
sample was collected by drilling into the center, which was then
decalcified and solubilized in 0.5 M EDTA, pH 8, and 5% sarkosyl at
25°C overnight, followed by digestion with 10 mg/ml proteinase K at 37°C overnight. A Centricon-30 filtration unit was used to collect glycopeptides (in the run-through), which were hydrolyzed in 80 vol of 4 M acetic acid at 80°C for 3 h to release Sias. Cations
were eliminated by using AG50W-X2 resin (H+ form) in water. After
lyophilization, the sample was resuspended in 10 mM acetic acid, and
the precipitate containing the acid form of EDTA was centrifuged out.
The sample was then diluted to a reading of <20 mosM, applied to an
AG1X8 anion exchange column (formate form), and Sias were eluted with 1 M formic acid. After passage through a SPICE C18 cartridge, the sample
was finally lyophilized. Sia recovery was confirmed in pilot
experiments using external sialoglycoprotein or internal
[3H]Neu5Ac standards. Purified samples were
derivatized with 1,2-diamino-4,5-methylene dioxybenzene (DMB), and
fluorescent DMB adducts (Ex = 373 nm,
Em = 448 nm) were resolved by reverse phase HPLC (27). The nature of the DMB derivatives of Sias was confirmed by mass
spectrometry (28). Peak areas corresponding to the expected elution
times of Sias were collected, concentrated, and analyzed by using a
Finnigan MAT HPLC with online mass spectrometer model LCQ-mass
spectrometer system A (28). A Varian C18 column was eluted
isocratically at 0.9 ml/min with 8% acetonitrile/7%
methanol/0.1% formic acid in water over 50 min, and the eluent
was monitored by UV absorbance at 373 nm and by electrospray ionization
mass spectrometry (capillary temperature 210°C, capillary voltage 31 V, and lens offset voltage 0 V). Spectra were acquired by scanning from
m/z 150-2000 in the positive-ion mode. In
some instances, MS/MS spectra were acquired by selecting the
parent mass and applying a 20% normalized collision energy. Data
analysis was performed using the XCALIBUR data
analysis program from the manufacturer.
Collection and Comparison of Alu Sequences.
Eighty-six intact AluYb8 elements that are human-specific
and fixed in human populations were picked up from a recently reported AluYb8 list (29) (see Supporting Text, which is
published as supporting information on the PNAS web site, www.pnas.org,
for a full list of sequences used for the analysis). The phylogenetic tree of each subfamily was made by the neighbor-joining method (30).
The actual number of nucleotide substitutions was calculated by
Kimura's two-parameter method (31). Poly(A) tails in the sequences
were excluded from the analysis.
Sequencing of Great Ape CMAH cDNAs.
Reverse transcription-PCR was performed on total RNA from
Epstein-Barr virus-transformed great ape lymphocytes (kindly provided by Peter Parham). The mRNA was reverse-transcribed by using 50 pmol of
random hexamer or CMAH-specific primer, 200 units of Superscript II,
and 20 units of RNase inhibitor in a 40-µl reaction with first-strand buffer, 200 µM dNTP, and 10 mM DTT. A 2-µl portion of the reverse transcription reaction was then PCR-amplified with Boehringer Mannheim's Expand Long Template PCR system with 2.25 mM
MgCl2 and detergents; 20 pmol each of primers
S5-Hom (GGCAGACGATGGGCAGCATCG) and A3-Hom (TGGATTCGTATCTACTACAG) were
used, based on homologous sequences of known murine, human, and chimp
CMAH genes. Some sequences were reamplified with a second round of PCR.
PCR products were resolved on 1% agarose gels, gel-purified, and
directly sequenced with 14 primers spanning both directions of the
entire CMAH sequence, based on homologous sequences from the murine,
human, and chimp. Data were verified visually and assembled into
contiguous sequences by using SEQUENCHER 3.1. Final
sequences are based on overlapping sequencing runs covering both strands.
Sias Can Be Purified from Bone and Fossil Samples.
Sias are traditionally isolated from soft tissues. We established a
modified protocol for Sia purification from highly mineralized bone
tissue. Normally, after soft-tissue samples are mechanically disrupted
and cells are lysed, the fraction of interest is subjected to mild acid
hydrolysis to release Sias from their attachment to sugar chains.
Released Sias are then purified by ion-exchange chromatography. In
keeping with prior experience with bony fossils (19), we used 5%
Sarkosyl and EDTA to demineralize and solubilize the powdered bone
samples. However, the high EDTA concentration inhibited subsequent
release of Sias by mild acid, which is normally performed using 2 M
acetic acid. Using known sialoglycoprotein standards, we established
that 80 vol of 4 M acetic acid were required to overcome the buffering
effect of EDTA and obtain proper release of Sias. The high
concentration of EDTA also inhibited subsequent binding of released
Sias to the anion-exchange column. This problem was overcome by
cation-exchange chromatography and subsequent precipitation of the
resulting hydrogen form of EDTA under acidic conditions. This was
followed by dilution to yield an electrolyte concentration of less than
20 mM, which no longer interferes with the anion-exchange step. In
early experiments, adequate Sia recovery was monitored by adding tracer
amounts of [3H]Neu5Ac to the starting samples.
As shown in Fig. 1A, this
modified protocol allowed the detection of Sias in contemporary human
and great ape bone samples. As expected, human bones gave only a single peak of Neu5Ac, whereas all great ape samples gave an easily detectable peak of Neu5Gc as well.
Evolution
Inactivation of CMP-N-acetylneuraminic acid
hydroxylase occurred prior to brain expansion during
human evolution
,
,
,
,
,
, and
Department of Biosystems
Science, Graduate University for Advanced Studies (Sokendai), Hayama,
Kanagawa 240-0193, Japan; § Max Planck Institute for
Evolutionary Anthropology, D-04103 Liepzig, Germany;
Gadjah Mada University, Yogyakarta, Indonesia; and
** Kenya National Museums, Nairobi, Kenya
![]()
Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
0.5-0.6 million
years ago (mya). Second, we date the insertion event of the
inactivating human-specific sahAluY element that replaced
the ancestral AluSq element found adjacent to exon 6 of the
CMAH gene in the chimpanzee genome. Assuming Alu source
genes based on a phylogenetic tree of human-specific Alu
elements, we estimate the sahAluY insertion time at
2.7
mya. Third, we apply molecular clock analysis to chimpanzee and other great ape CMAH genes and the corresponding human pseudogene to estimate
an inactivation time of
2.8 mya. Taken together, these studies
indicate that the CMAH gene was inactivated shortly before the time
when brain expansion began in humankind's ancestry,
2.1-2.2 mya.
In this regard, it is of interest that although Neu5Gc is the major
sialic acid in most organs of the chimpanzee, its expression is
selectively down-regulated in the brain, for as yet unknown reasons.
![]()
Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
i.e., it occurred after our last common ancestor with
chimpanzees but before the diaspora of present-day humans. This
mutation was apparently caused by a human-specific sahAluY
element that replaced an ancestral AluSq element found
adjacent to exon 6 of the CMAH gene in the genomes of great apes (18).
100,000 years (19, 20). We
therefore used three other independent methods to date the inactivation
of the human CMAH gene. First, we reasoned that Sias are more likely to
survive in fossils than DNA, as they are 9-carbon monosaccharide units
rather than polymers of nucleic acids. Thus, we directly analyzed
present-day human, great ape, and Neandertal and other fossil samples
for the presence of Neu5Ac and Neu5Gc. Second, we estimated the timing
of the Alu integration event that inactivated the human CMAH
(18). Finally, because pseudogenes have different rates of nucleotide
substitution as compared with active genes subject to selection, we
used the molecular clock approach to date the mutation in the human
CMAH gene (21).
![]()
Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (17K):
[in a new window]
Fig. 1.
Sias from bones and fossilized bones. Sias were released and purified,
derivatized with DMB, and analyzed by HPLC. The elution positions of
standard Neu5Ac and Neu5Gc are indicated. (A)
Contemporary bones of humans and great apes. (B)
Pleistocene and Miocene fossils. 1, mammoth tusk, Holocene,
1,000
years ago (kya); 2, cave bear jaw, Pleistocene, 40-80 kya; 3, deer leg bone, Pleistocene, 40-80 kya; and 4, dugong femur, Miocene,
20 mya.
Sias could also be recovered from some, but not all, Pleistocene and Miocene fossils (Fig. 1B). Although older fossil samples showed increasing contaminating peaks in the region where Sia DMB adducts eluted, their presence could be confirmed by mass spectrometry, where the primary ion masses and electron-impact fragmentation patterns corresponded to those expected for Neu5Ac and Neu5Gc (Fig. 2).
|
Neandertals, Like Humans, Lacked Neu5Gc Expression.
As shown in Fig. 3A, the HPLC
profile of Sias purified from the Neandertal-type specimen contained
Neu5Ac but no Neu5Gc. This particular sample was also originally
processed with great care to avoid contamination during the PCR
amplification of Neandertal mitochondrial DNA sequences (19). To
confirm that handling did not cause contamination, a control for the
processing steps was run alongside the test sample. This showed only a
very minor peak in the area of Neu5Ac. Neu5Gc and Neu5Ac do not show
any major differences in degradation rates under various conditions of
pH and temperature. Based on the amount of Neu5Ac recovered from the
Neandertal sample, Neu5Gc would have been detected if present at a
level higher than 0.04% of the total Sias. Fig. 3B shows the DMB-HPLC profiles of Sias extracted from two additional Neandertal specimens. The Neandertal tooth root ID no. 486 (from Sakajia, Georgia)
gave a finding very similar to the type specimen
i.e., clearly
detectable Neu5Ac but no Neu5Gc. In this case, there was sufficient Sia
recovered to confirm the Neu5Ac peak by mass spectrometry. We were
unable to isolate any Sias from the other Neandertal specimen, the
tooth root ID no. 2042 from Tsoutskhvati, Georgia.
|
It is very unlikely that positive samples were simply contaminated with
exogenous Sias. First, samples were collected from the center of the
specimen. Second, Sias are not present in plants, most invertebrates,
or most microorganisms (2). Third, only some samples contained Sias.
Fourth, blank controls incorporating all reagents and processing steps
ruled out significant contamination during handling (Fig.
3A). Thus, the CMAH gene inactivation predated the
human-Neandertal common ancestor
500,000-600,000 years ago (19).
Samples from H. erectus fossils found above the Solo River near Ngandong, Java in the mid-1900s, believed to be as recent as 50,000 years old (23), were examined, as were numerous faunal samples collected from sites (see Materials and Methods), where African bipedal hominid fossils had previously been found (24-26). Unfortunately, none of these samples yielded detectable Sias, indicating that the fossilization conditions at these sites were not conducive to Sias preservation. Based on these experiences, it is unlikely that current methods will allow us to recover and detect Sias from fossils found in tropical and subtropical regions. This is consistent with work by others indicating that the mean temperature in the area of fossilization is a major determinant of whether ancient DNA can be recovered (32).
Analysis of Alu Sequences to Time the Inactivation of the CMAH Gene.
The Alu family of transposable elements includes
primate-specific, nonautonomous retroposons comprising
10% of the
human genome (33, 34). Inactivation of CMAH evidently involved
replacement of an ancient AluSq present in the
human-chimpanzee ancestral genome with a younger sahAluY
(sialic acid hydroxylase
AluY) that is related to the AluYb8 subfamily
(18). We used the timing of human Alu integration events to
calculate the inactivation time of CMAH.
Individual members of Alu subfamilies seem to have arisen by
amplification of a small subset of "source" or "master"
genes (33, 35). Thus, the actual number of nucleotide differences between an Alu member and its source gene is directly
proportional to the age of the Alu member. Because the time
(t1) of the CMAH inactivation would be
equal to the insertion time (tsah) of
sahAluY, it can be estimated as
t1 = tsah = dsah/
, where
dsah is the actual number of
nucleotide substitutions between sahAluY and its source gene, and
is the nucleotide substitution rate of human
Alus per site per year. Kimura's two-parameter model (31)
is suitable for calculating the actual number of nucleotide
substitutions between two Alus because the transition rate
is approximately four times higher than the rate of transversion in
typical Alu sequences (36). To calculate
, we
used members of the AluYb8 subfamily. Because >99% of
AluYb8 subfamily members are human-specific (29), the
dissemination of AluYb8 elements would have started around
the divergence between humans and chimpanzees, and the oldest
human-specific AluYb8s would have inserted into the human genome immediately after the divergence. It is therefore assumed that
the age (tyb8) of the oldest
human-specific AluYb8 is equal to the divergence time
(t) between human and chimpanzee. Thus,
is
estimated by
= dyb8/tyb8 = dyb8/t, where
dyb8 is the actual number of
nucleotide substitutions that have accumulated in the oldest
AluYb8 lineage. Using the two formulas above, we derive the
following formula: t1 = (dsah/dyb8)t.
We have shown (18) that the CMAH inactivating sahAluY is most closely related to another human-specific AluY, msAluY (most similar AluY). According to the Alu amplification model (33, 35, 37), it is likely that both sahAluY and msAluY were disseminated from a single Alu source gene. We therefore prepared a phylogenetic tree with sahAluY, msAluY, and 86 intact human-specific AluYb8s that are fixed in human populations (ref. 29 and Fig. 4). This unrooted tree shows that whereas sahAluY and msAluY branch off from a common node, the branch length of msAluY is almost nil. We also estimated the branch length, leading to sahAluY and msAluY by selecting one AluYb8 member as an outgroup. These lengths are nearly the same, irrespective of the outgroup sequence (data not shown). It is therefore reasonable to assume that the sequence of msAluY is identical to that of the source gene that generated sahAluY and msAluY. By using sahAluY and msAluY, we obtain dsah = 0.022. The tree also shows that most AluYb8s branch off from a single point that represents 13 identical AluYb8 sequences. This suggests that most members might have been derived from a single source gene whose sequence is identical with those of these 13 AluYb8 elements. Based on the above considerations, the AluYb8-3 is then chosen as the oldest human-specific AluYb8 because this is the most distant relative of the assumed AluYb8 source gene (see Fig. 4). Interestingly, the assumed AluYb8 source gene is identical with the YAP (Y Alu polymorphic) element (38). Because the YAP element is dimorphic and has been recently integrated into the human genome, it is possible that its sequence is identical with that of true AluYb8 source gene. These findings strongly support our assumption on the AluYb8 source gene. By using the assumed AluYb8 source gene and the AluYb8-3 element, we obtain dyb8 = 0.043. We used the above data to derive an inactivation time of the CMAH gene of (0.512 ± 0.209)t. Using the human-chimpanzee divergence time (t) estimated below in the CMAH molecular clock analysis, we calculate that Alu-mediated inactivation of the CMAH gene occurred 2.7 ± 1.1 mya.
|
Dating the Inactivation of the CMAH Gene by Molecular Clock Analysis of the CMAH (Pseudo)Gene.
Once the human CMAH gene suffered an inactivating mutation and became a pseudogene, there would no longer have been a selective pressure to maintain the appropriate functional sequence. Therefore, nonsynonymous substitutions (nucleotide substitutions that produce a change in amino acid sequence) would have begun accumulating at the neutral mutation rate, the same rate at which synonymous substitutions that do not change amino acid sequences accumulate (21). In contrast, the orthologous genes in other primates would have continued under selection pressure, favoring synonymous substitutions over nonsynonymous substitutions. We have used this expected difference in mutation rates to calculate when the human CMAH mutation might have occurred.
When we assume that the neutral mutation rate is k,
the nonsynonymous substitution rate in a functional gene can be written as fNk, where
fN is the fraction of neutral
substitutions. The value fN is less
than or equal to unity and inversely relates to the degree of
functional constraint as 1
fN. This
fN varies from gene to gene depending
on the extent of functional importance. The more important the gene,
the smaller its fN. However, once it
becomes a pseudogene, fN becomes unity
and the rate increases to k. This increase in the
substitution rate at nonsynonymous sites is thus used to estimate the
time of inactivation of the CMAH gene.
For the human CMAH gene, we define t1
as the time elapsed since the inactivation and t as the time
after the human and chimpanzee lineages diverged from each other.
During t
t1, the
gene is functional so that the nonsynonymous sites evolve at a rate of fNk, whereas during
t1 the rate is k because of
the loss of function. Therefore, the per-site number of nonsynonymous
substitutions in the human lineage is expected to be
fNk(t
t1) + kt1. If we know
fN, k, and t, we
can estimate the value of t1.
The fN value for the functional CMAH gene is estimated as a ratio of the per site number of nonsynonymous substitutions to that of synonymous ones in non-human primate genes. To obtain an estimate of fN, we directly sequenced multiple CMAH cDNAs from all of the great apes and determined the total number of nonsynonymous and synonymous substitutions (nN and nS) along each lineage by the maximum parsimony method (Fig. 5). In all, nine sequences were used for this analysis (see Supporting Text for alignments of all of the sequences). In our original work comparing human and ape hydroxylase cDNAs, we noted some less common alternate forms of the human pseudogene transcript, including some insertions and deletions in the 3' region. A similar diversity was not seen in cDNAs from chimpanzee cells. We speculated that these human transcript variations reflect random degeneration in splicing precision of a nonfunctional gene. We have not pursued this issue further. For this particular study, we chose to sequence only the longest dominant human transcript that could be fully aligned with the great ape cDNA sequences. The 5' and 3' untranslated regions were excluded from this analysis because of a large deletion in humans, bonobos, and gorillas. The 92-bp region deleted in humans was also excluded from the analysis, as was a short segment at the end of the human transcripts that showed marked differences between the two human samples. The average values become nS = 17 and nN = 10. The number of synonymous and nonsynonymous sites is lS = 393 and lN = 1,236, respectively. We thus have fN = nNlS/nSlN = 0.19, suggesting rather strong selective constraint against the nonsynonymous substitutions in the functional CMAH gene (22).
|
The neutral mutation rate k is estimated as the synonymous
substitution rate under the assumption of no constraint on synonymous substitutions. To obtain k, we use the average number of
synonymous substitutions along the lineage leading to the human and the
great apes after their divergence of orangutans. The average number is
7.9. If we assume that the divergence time of orangutans is 13 mya, we have k = 7.9/393/(13 × 106) = 1.5 × 10
9 per site per year. Using this k
and the average number (3.1) of synonymous substitutions in the human
and chimpanzee lineages, we estimate the divergence time t
between the human and the chimpanzee as t = 3.1/393/k = 5.3 mya. Finally, the number
of nonsynonymous substitutions in the human CMAH gene is given by
6/1,236 = 4.9 × 10
3. Solving
the equation of fNk
(t
t1) + kt1 = 4.9 × 10
3 for
t1 with the estimates of
fN, k, and t, we
obtain t1 = [(4.9 × 10
3)/k
fNt]/(1
fN) = [(4.9 × 10
3)/(1.5 × 10
9)
0.19 × 5.3 × 106]/(1
0.19) = 2.8 × 106 years.
| |
Discussion |
|---|
|
|
|---|
We have shown that Sias can be purified from bones and from ancient fossils and specifically identified by DMB derivatization, HPLC separation, and mass spectrometry. This approach showed that Neandertals, like present-day humans, did not express Neu5Gc. This indicates that the hydroxylase was inactivated before the time of our common ancestor with Neandertals, likely about 500,000-600,000 years BP (19). Our failure to recover Sias from Javanese H. erectus samples and faunal fossils from Africa suggests that it may not be worthwhile to further study samples from tropical and semitropical areas, at least with presently available methods. Unfortunately, these are the regions where most of the more ancient bipedal hominids have been discovered. Thus, we used independent molecular approaches to estimate that the inactivating mutation in the hydroxylase occurred just over 2 mya. No single one of these approaches is free of potential error. However, when taken together, they allow us to reasonably date the inactivation of the hydroxylase to the period just before the appearance of Homo.
Since our last common ancestor with the chimpanzee, significant changes in teeth and jaw structure, bone-frame size, locomotion style, ontogeny period, and brain size have occurred during human evolution (39). Fossil records indicate that australopiths had large teeth, small brains, and skeletal structures adapted to a more terrestrial lifestyle. Whereas their pattern of locomotion is likely to have included some arboreality, they were fully bipedal and did show many signs of advanced bipedal bone structure. The 3.5 million-year-old Laetoli footprints of Australopithecus afarensis show human-like proportions, arches, heel strike, and convergent big toes (40). Comparative anatomical analysis of human, apes, and fossil hominids indicate that A. afarensis had significant features of bipedality (39, 41). Therefore, upright locomotion was acquired at the early stage of bipedal hominid evolution, and the inactivation of the hydroxylase could not have contributed to its establishment.
Starting at
2.1-2.2 mya in the bipedal hominid clade (relatively
soon after the approximated time of the CMAH mutation), one begins to
see significant increases in brain size relative to body size (39, 41).
Whereas the brains of early australopiths are in the size range of
modern great apes, an increase in brain size accelerated episodically
in later bipedal hominids, until the time of the first archaic H. sapiens about 400,000-500,000 years ago. This increase in brain
mass relative to body size (encephalization) is believed to be at least
partly related to secondary altriciality (incompletely developed and
helpless state of the newborn), and the relative increase of brain size
after birth (39, 42, 43). Unlike most primate brains that stop growing
relatively soon after birth, human brains continue to grow for some
time postnatally, at a rate similar to the body growth rate. Prenatal
growth of the head is limited by the size of the mother's birth canal.
Comparative anatomical analysis of humans and our earlier fossil
relatives had previously suggested that secondary altriciality
accompanied the appearance of brains of >750 cm3
(39), although a recent study suggested a later origin of secondary altriciality (43).
It is premature to speculate much regarding possible roles of CMAH gene inactivation in the acquisition of human-specific features. It is intriguing to note that, in all mammals studied so far (1), including the chimpanzee (4), the amount of Neu5Gc in the brain is always very low, no matter what the levels are in other organs of the body. This seems to be explained by selective down-regulation of CMAH gene expression in the mammalian brain (44). A potentially testable hypothesis is that the low levels of residual brain Neu5Gc in other mammals somehow limited brain expansion and that the human CMAH mutation released our ancestors from such a constraint. We are therefore studying the effects of Neu5Gc overexpression in the mouse brain and exploring how Neu5Gc expression might affect the biology of neural cells and molecules.
| |
Acknowledgements |
|---|
We gratefully acknowledge Susan Anton (Rutgers University) and Teuku Jacob (Gadjah Mada University) for helping to arrange contacts among the investigators. We thank Pascal Gagneux for helpful discussions and Yen-Liang Chen for helpful technical suggestions. This work was supported by U.S. Public Health Service Grant R01-GM323373 and by the G. Harold and Leila Y. Mathers Charitable Foundation.
| |
Abbreviations |
|---|
Sia, sialic acid; Neu5Gc, N-glycolylneuraminic acid; Neu5Ac, N-acetylneuraminic acid; mya, million years ago; DMB, 1,2-diamino-4,5-methylene dioxybenzene; CMAH, CMP-N-acetylneuraminic acid hydroxylase.
| |
Footnotes |
|---|
H.-H.C and T.H. contributed equally to this work.
¶ Present address: Theron Business Consulting, Munich, Germany.

To whom reprint requests should be addressed.
E-mail: avarki{at}ucsd.edu.
This paper was submitted directly (Track II) to the PNAS office.
Data deposition: The sequences reported in this paper have been deposited in the GenBank database (accession nos. AF494221, AF494222, AF494223, AF494224, and AF494225).
| |
References |
|---|
|
|
|---|
| 1. | Schauer, R. (1982) Sialic Acids: Chemistry, Metabolism and Function, Cell Biology Monographs (Springer, New York), Vol. 10. |
| 2. | Angata, T. & Varki, A. (2002) Chem. Rev. 102, 439-470[CrossRef][ISI][Medline] . |
| 3. | Varki, A. (2002) Yearbook Phys. Anthropol. 44, 54-69. |
| 4. | Muchmore, E. A. , Diaz, S. & Varki, A. (1998) Am. J. Phys. Anthropol. 107, 187-198[CrossRef][ISI][Medline] . |
| 5. |
Chou, H. H.
, Takematsu, H.
, Diaz, S.
, Iber, J.
, Nickerson, E.
, Wright, K. L.
, Muchmore, E. A.
, Nelson, D. L.
, Warren, S. T.
& Varki, A.
(1998)
Proc. Natl. Acad. Sci. USA
95,
11751-11756 |
| 6. |
Irie, A.
, Koyama, S.
, Kozutsumi, Y.
, Kawasaki, T.
& Suzuki, A.
(1998)
J. Biol. Chem.
273,
15866-15871 |
| 7. |
Bouhours, D.
& Bouhours, J. F.
(1983)
J. Biol. Chem.
258,
299-304 |
| 8. | Muchmore, E. , Varki, N. , Fukuda, M. & Varki, A. (1987) FASEB J. 1, 229-235[Abstract]. |
| 9. |
Muchmore, E. A.
(1992)
Glycobiology
2,
337-343 |
| 10. |
Brinkman-Van der Linden, E. C. M.
, Sjoberg, E. R.
, Juneja, L. R.
, Crocker, P. R.
, Varki, N.
& Varki, A.
(2000)
J. Biol. Chem.
275,
8633-8640 |
| 11. |
Collins, B. E.
, Fralich, T. J.
, Itonori, S.
, Ichikawa, Y.
& Schnaar, R. L.
(2000)
Glycobiology
10,
11-20 |
| 12. |
Ito, T.
, Suzuki, Y.
, Suzuki, T.
, Takda, A.
, Horimoto, T.
, Wells, K.
, Kida, H.
, Otsuki, K.
, Kiso, M.
, Ishida, H.
& Kawaoka, Y.
(2000)
J. Virol.
74,
9300-9305 |
| 13. | Ito, T. , Suzuki, Y. , Mitnaul, L. , Vines, A. , Kida, H. & Kawaoka, Y. (1997) Virology 227, 493-499[CrossRef][ISI][Medline] . |
| 14. | Suzuki, T. , Horiike, G. , Yamazaki, Y. , Kawabe, K. , Masuda, H. , Miyamoto, D. , Matsuda, M. , Nishimura, S. I. , Yamagata, T. , Ito, T. , et al. (1997) FEBS Lett. 404, 192-196[CrossRef][ISI][Medline] . |
| 15. |
Delorme, C.
, Brüssow, H.
, Sidoti, J.
, Roche, N.
, Karlsson, K. A.
, Neeser, J. R.
& Teneberg, S.
(2001)
J. Virol.
75,
2276-2287 |
| 16. | Kyogashima, M. , Ginsburg, V. & Krivan, H. C. (1989) Arch. Biochem. Biophys. 270, 391-397[CrossRef][ISI][Medline] . |
| 17. | Schlenzka, W. , Shaw, L. , Kelm, S. , Schmidt, C. L. , Bill, E. , Trautwein, A. X. , Lottspeich, F. & Schauer, R. (1996) FEBS Lett. 385, 197-200[CrossRef][Medline] . |
| 18. |
Hayakawa, T.
, Satta, Y.
, Gagneux, P.
, Varki, A.
& Takahata, N.
(2001)
Proc. Natl. Acad. Sci. USA
98,
11399-11404 |
| 19. | Krings, M. , Stone, A. , Schmitz, R. W. , Krainitzki, H. , Stoneking, M. & Paabo, S. (1997) Cell 90, 19-30[CrossRef][ISI][Medline] . |
| 20. | Hofreiter, M. , Serre, D. , Poinar, H. N. , Kuch, M. & Paabo, S. (2001) Nat. Rev. Genet. 2, 353-359[CrossRef][ISI][Medline] . |
| 21. | Li, W.-H. (1997) Molecular Evolution (Sinauer, Sunderland, MA). |
| 22. | Gabunia, L. & Vekua, A. (1990) L'Anthropologie (Paris) 94, 643-650. |
| 23. |
Swisher, C. C.
, Rink, W. J.
, Anton, S. C.
, Schwarcz, H. P.
, Curtis, G. H.
, Suprijo, A.
& Widiasmoro
(1996)
Science
274,
1870-1874 |
| 24. | Ward, C. V. , Leakey, M. G. & Walker, A. W. (2001) J. Hum. Evol. 41, 255-376[CrossRef][ISI][Medline] . |
| 25. | Brown, F. , Harris, J. , Leakey, R. & Walker, A. (1985) Nature (London) 316, 788-792[CrossRef][Medline] . |
| 26. | Leakey, R. E. & Walker, A. (1988) Am. J. Phys. Anthropol. 76, 1-24[CrossRef][ISI][Medline] . |
| 27. | Manzi, A. E. , Diaz, S. & Varki, A. (1990) Anal. Biochem. 188, 20-32[CrossRef][ISI][Medline] . |
| 28. |
Klein, A.
, Diaz, S.
, Ferreira, I.
, Lamblin, G.
, Roussel, P.
& Manzi, A. E.
(1997)
Glycobiology
7,
421-432 |
| 29. | Carroll, M. L. , Roy-Engel, A. M. , Nguyen, S. V. , Salem, A. H. , Vogel, E. , Vincent, B. , Myers, J. , Ahmad, Z. , Nguyen, L. , Sammarco, M. , et al. (2001) J. Mol. Biol. 311, 17-40[CrossRef][ISI][Medline] . |
| 30. | Saitou, N. & Nei, M. (1987) Mol. Biol. Evol. 4, 406-425[Abstract]. |
| 31. |
Kimura, M.
(1981)
Proc. Natl. Acad. Sci. USA
78,
454-458 |
| 32. | Smith, C. I. , Chamberlain, A. T. , Riley, M. S. , Cooper, A. , Stringer, C. B. & Collins, M. J. (2001) Nature (London) 410, 771-772. |
| 33. |
Schmid, C. W.
(1998)
Nucleic Acids Res.
26,
4541-4550 |
| 34. | Lander, E. S. , Linton, L. M. , Birren, B. , Nusbaum, C. , Zody, M. C. , Baldwin, J. , Devon, K. , Dewar, K. , Doyle, M. , FitzHugh, W. , et al. (2001) Nature (London) 409, 860-921[CrossRef][Medline] . |
| 35. | Schmid, C. & Maraia, R. (1992) Curr. Opin. Genet. Dev. 2, 874-882[CrossRef][Medline] . |
| 36. | Kapitonov, V. & Jurka, J. (1996) J. Mol. Evol. 42, 59-65[CrossRef][ISI][Medline] . |
| 37. |
Zietkiewicz, E.
, Richer, C.
, Makalowski, W.
, Jurka, J.
& Labuda, D.
(1994)
Nucleic Acids Res.
22,
5608-5612 |
| 38. | Hammer, M. F. (1994) Mol. Biol. Evol. 11, 749-761[Abstract]. |
| 39. |
Wood, B.
& Collard, M.
(1999)
Science
284,
65-66 |
| 40. | Leakey, M. D. , Hay, R. L. , Curtis, G. H. , Drake, R. E. & Jackes, M. K. (1976) Nature (London) 262, 460-466[CrossRef][Medline] . |
| 41. |
McHenry, H. M.
(1994)
Proc. Natl. Acad. Sci. USA.
91,
6780-6786 |
| 42. | Jones, S. , Martin, R. & Pilbeam, D. (1992) The Cambridge Encyclopedia of Human Evolution (Cambridge Univ. Press, New York). |
| 43. | Dean, C. , Leakey, M. G. , Reid, D. , Schrenk, F. , Schwartz, G. T. , Stringer, C. & Walker, A. (2001) Nature (London) 414, 628-631[CrossRef][Medline] . |
| 44. |
Kawano, T.
, Koyama, S.
, Takematsu, H.
, Kozutsumi, Y.
, Kawasaki, H.
, Kawashima, S.
, Kawasaki, T.
& Suzuki, A.
(1995)
J. Biol. Chem.
270,
16458-16463 |
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
Z. D. Zhang, P. Cayting, G. Weinstock, and M. Gerstein Analysis of Nuclear Receptor Pseudogenes in Vertebrates: How the Silent Tell Their Stories Mol. Biol. Evol., January 1, 2008; 25(1): 131 - 143. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Walker and J. Lowe Quaternary science 2007: a 50-year retrospective Journal of the Geological Society, December 1, 2007; 164(6): 1073 - 1092. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ebersberger, P. Galgoczy, S. Taudien, S. Taenzer, M. Platzer, and A. von Haeseler Mapping Human Genetic Ancestry Mol. Biol. Evol., October 1, 2007; 24(10): 2266 - 2276. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C M Brinkman-Van der Linden, N. Hurtado-Ziola, T. Hayakawa, L. Wiggleton, K. Benirschke, A. Varki, and N. Varki Human-specific expression of Siglec-6 in the placenta Glycobiology, September 1, 2007; 17(9): 922 - 931. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. K. Altheide, T. Hayakawa, T. S. Mikkelsen, S. Diaz, N. Varki, and A. Varki System-wide Genomic and Biochemical Comparisons of Sialic Acid Biology Among Primates and Rodents: EVIDENCE FOR TWO MODES OF RAPID EVOLUTION J. Biol. Chem., September 1, 2006; 281(35): 25689 - 25702. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yin, A. Hashimoto, M. Izawa, K. Miyazaki, G.-Y. Chen, H. Takematsu, Y. Kozutsumi, A. Suzuki, K. Furuhata, F.-L. Cheng, et al. Hypoxic culture induces expression of sialin, a sialic Acid transporter, and cancer-associated gangliosides containing non-human sialic Acid on human cancer cells. Cancer Res., March 15, 2006; 66(6): 2937 - 2945. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hayakawa, I. Aki, A. Varki, Y. Satta, and N. Takahata Fixation of the Human-Specific CMP-N-Acetylneuraminic Acid Hydroxylase Pseudogene and Implications of Haplotype Diversity for Human Evolution Genetics, February 1, 2006; 172(2): 1139 - 1146. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Varki and T. Angata Siglecs--the major subfamily of I-type lectins Glycobiology, January 1, 2006; 16(1): 1R - 27R. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Varki and T. K. Altheide Comparing the human and chimpanzee genomes: Searching for needles in a haystack Genome Res., December 1, 2005; 15(12): 1746 - 1758. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Martin, J. C. Rayner, P. Gagneux, J. W. Barnwell, and A. Varki Evolution of human-chimpanzee differences in malaria susceptibility: Relationship to human genetic loss of N-glycolylneuraminic acid PNAS, September 6, 2005; 102(36): 12819 - 12824. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Nguyen, P. Tangvoranuntakul, and A. Varki Effects of Natural Human Antibodies against a Nonhuman Sialic Acid That Metabolically Incorporates into Activated and Malignant Immune Cells J. Immunol., July 1, 2005; 175(1): 228 - 236. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. H. Perry, B. C. Verrelli, and A. C. Stone Compar |